VBI Vaccines Reports Successful Shareholder Voting Results and Promising Interim Data on Cancer Vaccine at ASCO Annual Meeting
Cambridge-based biopharmaceutical company, VBI Vaccines Inc. (Nasdaq: VBIV), recently announced positive outcomes from its annual general meeting of shareholders held on June 25, 2024. The meeting saw a significant representation of common shares, indicating strong investor interest and support for the company’s immunology-driven approach to disease prevention and treatment.
The results of the meeting indicate the shareholders’ confidence in VBI Vaccines and their enthusiasm for the company’s endeavors. The number of common shares represented by shareholders present in person or by proxy at the meeting was substantial, reflecting a high level of engagement from shareholders. This level of participation is a positive sign for the company’s future prospects.
In addition, VBI Vaccines shared exciting news regarding the latest interim data from its Phase 2b study of VBI-1901, a cancer vaccine immunotherapeutic candidate for recurrent glioblastoma (GBM) patients. The data were accepted for poster presentation at the prestigious 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
The promising interim tumor response data from the ongoing randomized, controlled Phase 2b study demonstrates the potential efficacy of VBI-1901 in treating recurrent GBM. This is a significant milestone for VBI Vaccines, further validating the potential of its immunology-focused approach to cancer therapy.
Alongside these positive updates, VBI Vaccines also provided a business update and announced financial results for the first quarter of 2024. The company’s focus has been on pipeline execution, expanding access and uptake of PreHevbrio in targeted market segments, and forming strategic partnerships to drive opportunities.
These recent developments highlight VBI Vaccines’ commitment to advancing innovative solutions for disease prevention and treatment. With promising shareholder voting results, positive interim data, and a solid business strategy, VBI Vaccines is well-positioned to make significant contributions to the field of biopharmaceuticals.
Comments